Navigation Links
Argos Therapeutics Announces Additional $17.5 Million Of Series E Financing Bringing Total Commitment To $60 Million
Date:11/20/2013

DURHAM, N.C., Nov. 20, 2013 /PRNewswire/ -- Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform, today announced that on November 4, 2013, the Company increased the size of its previously announced Series E financing by $17.5 million, bringing the total amount of committed funds from $42.5 million to $60 million.

In August 2013, Argos announced the closing of a $42.5 million Series E financing.  The additional $17.5 million investment represents additional commitments from current Argos investors and one new investor. The funds from the Series E financing will be used to support the Company's ongoing ADAPT pivotal Phase 3 clinical trial of AGS-003 for the treatment of metastatic renal cell carcinoma (mRCC). 

"This funding further strengthens our ability to advance our ADAPT clinical trial.  In addition, the company is now better positioned to consider and pursue a range of options to support our global manufacturing and commercialization plans based on the potential of our Arcelis™ technology platform," said Jeff Abbey, Argos' president and chief executive officer.

About the Arcelis™ Technology Platform
Arcelis is a fully personalized immunotherapy technology that captures mutated and variant antigens that are specific to each patient's disease. It is designed to overcome immunosuppression by producing a durable memory T cell response without adjuvants that may be associated with toxicity. The technology is potentially applicable to a wide range of different cancers and infectious diseases and is designed to overcome many of the manufacturing and commercialization challenges that have impeded other personalized immunotherapies.

The Arcelis process uses only a small tumor or blood sample and the patient's own dendritic cells, which are collected and optimized following a single leukapheresis procedure. The proprietary process uses RNA isolated from the patient's disease sample to program dendritic cells to target disease antigens. The activated, antigen-loaded dendritic cells are then formulated into the patient's plasma and administered via intradermal injection.

About Argos Therapeutics
Argos Therapeutics is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform.  Argos' most advanced product candidate, AGS-003, has initiated a pivotal Phase 3 study for the treatment of mRCC, and the Company recently completed enrollment of its Phase 2b study of AGS-004 for the treatment of HIV. For more information about Argos Therapeutics, visit www.argostherapeutics.com.


'/>"/>
SOURCE Argos Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
2. Study Results Demonstrate Analytical Treatment Interruption to Assess Antiviral Activity of Argoss Arcelis™ Personalized Immunotherapy for Treatment of HIV Patients, AGS-004, Is Acceptable Strategy for At Least 16 Weeks
3. Argos Confirms Improved RNA Amplification Protocol Enhances Quality of Antigen-Specific Immune Response
4. Argos Therapeutics to Present at the Elsevier Therapeutic Area Partnerships Meeting
5. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
6. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
7. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
8. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
9. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
10. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
11. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... , Jan. 19, 2017 This report ... current and future scenario of the global market. Large ... opioid consumption. Severe chronic constipation is a major side ... traditional laxatives. Hence, novel targeted therapy has been prescribed ... sufferers, launch of targeted medicines, and growing awareness about ...
(Date:1/19/2017)... Accuray Incorporated (Nasdaq: ARAY ) ... to set the bar for excellence in customer satisfaction. ... satisfaction rating among radiation treatment delivery systems in the ... Intelligence Briefing™. The most recent ratings trend also shows ... peers for 11 of the past 12 quarters. ...
(Date:1/19/2017)... January 19, 2017 Shire plc ... the U.S. Food and Drug Administration (FDA) has acknowledged ... Drug Application (NDA) for SHP465, a long-acting, triple-bead, mixed ... potential once-daily treatment for Attention-Deficit/Hyperactivity Disorder (ADHD). The FDA ... June 20, 2017, the designated Prescription Drug User Fee ...
Breaking Medicine Technology:
(Date:1/22/2017)... ... January 22, 2017 , ... "Photo Cloud allows FCPX users to ... 3D slideshow with complete ease," said Christina Austin - CEO of Pixel Film Studios. ... the FCPX timeline. Presets include scenes with one, three, four or five ...
(Date:1/21/2017)... ... January 21, 2017 , ... Caronlab Australia, an Australian ... January ECRM Trade Show in Hilton Head, SC, where it benefited from outstanding meetings ... quality of its beauty and wellness products. At this trade show, the company had ...
(Date:1/21/2017)... ... ... "ProDOF is the perfect set of tools for video editors that want to create the ... Austin - CEO of Pixel Film Studios. , Video editors using ProDOF can add ... DSLR racking focus from one area into the next. ProDOF comes with 0.5 second, ...
(Date:1/21/2017)... ... January 21, 2017 , ... Phytocéane invites you to take an ... of the world with ZANZIBAR SHOWER GEL. Inspired by the beauty of Zanzibar, a ... Oil and moisturizing vegetal coral to create this gentle, crystal-clear shower gel to cleanse ...
(Date:1/21/2017)... ... January 21, 2017 , ... Northern California Medical Associates ... joined their multi-specialty medical group. The dermatology practice provides general dermatologic treatment, outpatient ... to add this excellent dermatology practice to our group’s medical services,” explains NCMA ...
Breaking Medicine News(10 mins):